The present invention relates to pharmaceutical formulations comprising azacitidine or its pharmaceutically acceptable salts. Further, the invention relates to processes for preparing the stable formulations comprising azacitidine or salts thereof, and methods of using the formulations for treating various types of cancer disorders in mammals.